(101) observed that the antithrombotic drug polydatin blocked the AKT/STAT3/FOXO1 signaling pathway in HCC cells, which increased the levels of phosphorylated AKT, phosphorylated Janus kinase 1, and STAT3, thereby blocking FOXO1. This evidence concerns the gene FOXO1 and hepatocellular carcinoma.